Table 1.

Clinical characteristics of patients at baseline, including cancer types, prior therapies, and enrollment

Baseline characteristicAll patients (N = 135)
Age
 Median (range), years62 (21–85)
 ≥65 year63 (47)
Sex, n (%)
 Male83 (61)
 Female52 (39)
ECOG performance status, n (%)
 045 (33)
 190 (67)
Prior immune therapy, n (%)
 Yes69 (51)
 No66 (49)
Prior BRAFi/MEKi therapy, n (%)
 Yes32 (24)
 No103 (76)
Pretreatment LDH, n (%)
 Elevated43 (32)
 Not elevated50 (37)
 Not done42 (31)
Body mass index
 Median (range), kg/m226.83 (14.6–148.2)
Primary cancer type, n (%)
 Melanoma53 (39)
 Colorectal26 (19)
 Non–small cell lung19 (14)
 Papillary thyroid6 (4)
 Glioblastoma4 (3)
 Prostate3 (2)
 Small intestine3 (2)
 Othera21 (16)
Enrollment, n (%)
 Dose escalation27 (20)
BRAF colorectal cohort17 (13)
BRAF non–small cell lung cohort16 (12)
BRAF melanoma cohort21 (16)
BRAF other cancer cohort24 (18)
NRAS melanoma cohort22 (16)
MEK cancer cohort8 (6)
  • NOTE. Data are presented as N (%) unless indicated otherwise.

  • aIncludes adenoid cystic, angiosarcoma, appendiceal, cecum, cholangiocarcinoma, gallbladder, gastrointestinal stromal tumor, mediastinal non-seminomatous germ cell tumor, mesothelioma, ovarian, pancreatic, salivary duct, small cell lung, squamous cell, thyroid, urachal, and vaginal.